Sprycel is a targeted therapy that works by binding to and inhibiting the BCR-ABL tyrosine kinase. This kinase is constitutively active in CML due to the Philadelphia chromosome abnormality. By blocking this kinase, Dasatinib is able to inhibit the downstream signaling pathways that drive the overproduction of white blood cells in CML. Inhibition of BCR-ABL leads to apoptosis of CML c... https://prachicmi.livepositively.com/sprycel-a-potent-treatment-option-for-chronic-myeloid-leukemia/new=1